Michael Kaleko

4.7k citations

76 papers · 3.9k indexed · h-index 37

Genetics top 0.5%
- Virus-based gene therapy research 37
Oncology top 2%
- CAR-T cell therapy research 10
Molecular Biology top 2%
- CRISPR and Genetic Engineering 11
- Viral Infectious Diseases and Gene Expression in Insects 11
- RNA Interference and Gene Delivery 10
Hematology top 2%
- Hemophilia Treatment and Research 14
Endocrinology, Diabetes and Metabolism top 2%
Infectious Diseases
- Clostridium difficile and Clostridium perfringens research 12
Molecular Medicine
- Antibiotic Resistance in Bacteria 11

Co-authors: A. Dusty Miller Sheila Connelly Alan McClelland William J. Rutter Theodore A Smith Dawn B. Kayda Michele G. Mehaffey Neeraja Idamakanti
Cited by: Genetics Oncology Molecular Biology
Journals: Human Gene Therapy (15 papers)Blood (9 papers)Journal of Cellular Physiology (5 papers)
Partner nations: United States Switzerland South Africa

In The Last Decade

Michael Kaleko

75 papers receiving 3.8k citations

Peers

Countries citing papers authored by Michael Kaleko

Since Specialization

Citations

This map shows the geographic impact of Michael Kaleko's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Kaleko with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Kaleko more than expected).

Fields of papers citing papers by Michael Kaleko

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Kaleko. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Kaleko. The network helps show where Michael Kaleko may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Michael Kaleko, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Michael Kaleko Line = papers co-authored together Michael Kaleko links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	2216MO VIRAGE trial: Randomized phase IIb, open-label, study of nab-paclitaxel and gemcitabine with/without intravenous VCN-01 in patients with metastatic pancreatic cancer (mPDAC) Annals of Oncology ·董明权,Roberto Pazo-Cid,T. Macarulla Mercadé,Berta Laquente,Feng Don,(unknown),Andrés J. Muñoz Martín,Lani Estrada Sakay,CAIYan-fei,Tara Elisabeth Seery,Conferêcia Europeia de Provinciais Jesuitas,Chris Nevala-Plagemann,Vivek Sharma,Eva Martínez de Castro,C. Le,Michael Kaleko,Ahmad Ab. Majid,C. Blasco,Tovey Stephen C.,Manuel Hidalgo	2025	0
2	VIRAGE: A phase IIb, open-label, randomized study of nab-paclitaxel and gemcitabine plus/minus VCN-01 in patients with metastatic pancreatic cancer. Journal of Clinical Oncology ·Rocio García‐Carbonero,Roberto Pazo-Cid,Teresa Macarulla,Feng Don,Edward Kim,Berta Laquente,Tara Elisabeth Seery,CAIYan-fei,Carmen Guillén‐Ponce,Eva Martínez de Castro,Ajit Ranade,Andrés J. Muñoz Martín,Nathan A. Palm,Ignacio Garrido‐Laguna,EunChong Lee,Michael Kaleko,Ahmad Ab. Majid,C. Blasco,Manel Cascalló,Manuel Hidalgo	2024	1
3	Low dose oral beta-lactamase protects the gut microbiome from oral beta-lactam-mediated damage in dogs AIMS Public Health ·Sheila Connelly,Brian Fanelli,Nur A. Hasan,Rita R. Colwell,Michael Kaleko	2019	6
4	620. Oral β-Lactamase Therapies Prevent Microbiome Damage and Attenuate Antibiotic Resistance From IV and Oral Antibiotics in Large Animal Models of Antibiotic-Mediated Gut Dysbiosis Open Forum Infectious Diseases ·Sheila Connelly,Christian Furlan-Freguia,Brian Fanelli,Nur A. Hasan,Rita R. Colwell,Michael Kaleko	2018	2
5	Distinct consequences of amoxicillin and ertapenem exposure in the porcine gut microbiome Anaerobe ·Sheila Connelly,Poorani Subramanian,Nur A. Hasan,Rita R. Colwell,Michael Kaleko	2018	31
6	Development of SYN-004, an oral beta-lactamase treatment to protect the gut microbiome from antibiotic-mediated damage and prevent Clostridium difficile infection Anaerobe ·Michael Kaleko,J. Andrew Bristol,V. G. Kniazev,Todd B. Parsley,Giovanni Widmer,Saul Tzipori,Poorani Subramanian,Nur A. Hasan,Francenila Rodrigues,John F. Kokai‐Kun,Joseph Sliman,Annie Jones,Sheila Connelly	2016	55
7	Angiopoietin‐2 enhances retinal vessel sensitivity to vascular endothelial growth factor Journal of Cellular Physiology ·Yuji Oshima,Tye Deering,Sachiko M. Oshima,Hiroyuki Nambu,P. Seshidhar Reddy,Michael Kaleko,Sheila Connelly,Sean F. Hackett,Peter A. Campochiaro	2004	77
8	Intraocular gutless adenoviral‐vectored VEGF stimulates anterior segment but not retinal neovascularization Journal of Cellular Physiology ·Yuji Oshima,Kyoichi Takahashi,Sachiko M. Oshima,Yoshitsugu Saishin,Yumiko Saishin,Yuuya OHNISHI,P.R. Roelfsema,P. Seshidhar Reddy,Shanthi Ganesh,Terrence W. Brann,Gene Liau,Michael Kaleko,Sheila Connelly,Peter A. Campochiaro	2004	14
9	Potentiation of oncolytic adenoviral vector efficacy with gutless vectors encoding GMCSF or TRAIL Cancer Gene Therapy ·Kevin D. Burroughs,Dawn B. Kayda,Kiran Sakhuja,Neil Brenner,John Jakubczak,J. Andrew Bristol,David L. Ennist,Paul L. Hallenbeck,Michael Kaleko,Sheila Connelly	2004	8
10	Development of adenovirus serotype 35 as a gene transfer vector Virology ·P. Seshidhar Reddy,Shanthi Ganesh,Taylor,Terrence W. Brann,W. Kojnoff,Michele Kaloss,Michael Kaleko,Sheila Connelly	2003	108
11	Mapping of the Bovine Immunodeficiency Virus Packaging Signal and RRE and Incorporation into a Minimal Gene Transfer Vector Virology ·Ziyanda Majokweni,M. S. P. Sumaiya,Simone Pfeifer,Jingli Zhang,Michael Kaleko,Tianci Luo	2002	9
12	Sustained Human Factor VIII Expression in Hemophilia A Mice Following Systemic Delivery of a Gutless Adenoviral Vector Molecular Therapy ·P. Seshidhar Reddy,Kiran Sakhuja,Shanthi Ganesh,Lijuan Yang,Dawn B. Kayda,Terrence W. Brann,Scott Pattison,知佐宿南,Neeraja Idamakanti,W. Kojnoff,Michele Kaloss,Catherine Barjot,Jeffrey S. Chamberlain,Michael Kaleko,Sheila Connelly	2002	89
13	In Vivo Dose Threshold Effect of Adenovirus-Mediated Factor VIII Gene Therapy in Hemophiliac Mice Molecular Therapy ·J. Andrew Bristol,Pamela S. Shirley,Neeraja Idamakanti,Michael Kaleko,Sheila Connelly	2000	37
14	In Vivo Evaluation of an Adenoviral Vector Encoding Canine Factor VIII: High-Level, Sustained Expression in Hemophiliac Mice Human Gene Therapy ·بدر بن ناصر بن محمد القحطاني,Pamela S. Shirley,J. Andrews,Dawn B. Kayda,W. Kojnoff,Michele Kaloss,S Tinlin,Cheryl Cameron,Colleen Notley,Christine Hough,David Lillicrap,Michael Kaleko,Sheila Connelly	1999	36
15	An Improved Method for Generating Retroviral Producer Clones for Vectors Lacking a Selectable Marker Gene Blood Cells Molecules and Diseases ·Derek A. Persons,Michele G. Mehaffey,Michael Kaleko,Arthur W. Nienhuis,Elio F. Vanin	1998	74
16	High-Level Tissue-Specific Expression of Functional Human Factor VIII in Mice Human Gene Therapy ·Sheila Connelly,Tahani K. Hawsawi,Alan McClelland,Michael Kaleko	1996	57
17	Adenovirus mediated expression of therapeutic plasma levels of human factor IX in mice Nature Genetics ·Theodore A Smith,Michele G. Mehaffey,Dawn B. Kayda,Cheyenne Allenby,Soonpin Yei,Bruce C. Trapnell,Alan McClelland,Michael Kaleko	1993	295
18	Ligand‐dependent inhibition of myoblast differentiation by overexpression of the type‐1 insulin‐like growth factor receptor Journal of Cellular Physiology ·LeBris S. Quinn,Oskar Johansson,E. Bissaldi,Michael Kaleko	1993	19
19	Transformation mediated by the human HER-2 gene independent of the epidermal growth factor receptor. PubMed ·Secília Rodrigues Rosa,Michael Kaleko,A. Dusty Miller,Dennis J. Slamon	1992	138
20	Long-Term Expression of Human Adenosine Deaminase in Mice after Transplantation of Bone Marrow Infected with Amphotropic Retroviral Vectors Human Gene Therapy ·William Osborne,Randy A. Hock,Michael Kaleko,A. Dusty Miller	1990	54

About Michael Kaleko

Michael Kaleko is a scholar working on Molecular Medicine, Hematology and Genetics, having authored 76 papers that have together received 3.9k indexed citations. Recurring topics across this work include Virus-based gene therapy research (37 papers), Hemophilia Treatment and Research (14 papers), Clostridium difficile and Clostridium perfringens research (12 papers), CRISPR and Genetic Engineering (11 papers), Viral Infectious Diseases and Gene Expression in Insects (11 papers), Antibiotic Resistance in Bacteria (11 papers), RNA Interference and Gene Delivery (10 papers) and CAR-T cell therapy research (10 papers). The work is most often cited by research in Genetics (2.1k citations), Oncology (1.1k citations) and Molecular Biology (2.6k citations). Michael Kaleko has collaborated with scholars based in United States, Switzerland and South Africa. Frequent co-authors include A. Dusty Miller, Sheila Connelly, Alan McClelland, William J. Rutter, Theodore A Smith, Dawn B. Kayda, Michele G. Mehaffey, Neeraja Idamakanti, J. Victor Garcia and Bruce C. Trapnell. Their work appears in journals such as Human Gene Therapy, Blood, Journal of Cellular Physiology, Open Forum Infectious Diseases and Molecular Therapy.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact